Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Linagliptin and metformin hydrochloride

(Jentadueto®)

Jentadueto®

Drug updated on 12/11/2024

Dosage FormTablet (oral; linagliptin/ metformin; 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1,000 mg)
Drug ClassDipeptidyl peptidase-4 (DPP-4) inhibitors and biguanides
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two randomized controlled trial(s). [1-2]
  • In patients with impaired glucose tolerance, the linagliptin + metformin (LM) group demonstrated a significant reduction in glucose levels during oral glucose tolerance test (OGTT) (area under the glucose curve (AUCgluc) (0-120min): -4425 ± 871 vs. -1116 ± 1104 mg/dl/120 min, p < 0.001) and improved pancreatic beta-cell function (2.3 ± 0.23 vs. 1.7 ± 0.27, p = 0.001) compared to metformin alone.
  • Over 24 months, patients with prediabetes and two additional type 2 diabetes (T2D) risk factors in the LM group had a higher probability of regression to normoglycemia (odds ratio (OR) 3.26, 95% confidence interval (CI) 1.55-6.84) and a lower incidence of T2D (hazard ratio (HR) 4.0, 95% CI 1.24-13.04, p = 0.020) than those on metformin alone.
  • The LM group showed greater improvements in pancreatic beta-cell function, with the disposition index increasing from 1.31 (95% CI: 1.14-1.49) to 2.41 (95% CI: 2.10-2.72) at 6 months and to 2.07 (95% CI: 1.82-2.31) at 24 months, compared to smaller increases in the metformin group (p < 0.05).